Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

New research has been published in the journal Allergy that looks at how the body undergoes immunological changes that may support remission of peanut allergies in children. Previously there was little known how the body successfully acquires remission of the peanut allergy, and this article uses probiotic peanut oral immunotherapy to analyze this more in depth.
 
The study included 62 children from Australia aged between 1 and 10 years who were peanut allergic. The children were split into two groups, one that received a combination treatment of probiotic and oral immunotherapy, and another which acted as a placebo. The trial lasted 18 months, and at the end of the treatment, it was found that 74% of those in the treatment group achieved remission, while only 4% in the placebo group. The key finding from this study was that the researchers gained insights into how remission was acquired; specific gene networks and their rewiring were identified as drivers of peanut allergy remission.
 
As a result of this research, there is a better understanding of how probiotic oral immunotherapy can lead to peanut allergy remission in children. This will help in identifying targeted practices to induce remission in those patients who have a peanut allergy.

Ashley, S.E., et al. (2022) Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks. Allergy.

Join us

Sign up to become a member of the INC and discover the benefits of INC membership. Or subscribe and have access to our magazine, industry newsletters and industry directory.

Privacy Preference Center